[go: up one dir, main page]

WO2007046083A3 - Compositions for treatment of eye diseases - Google Patents

Compositions for treatment of eye diseases Download PDF

Info

Publication number
WO2007046083A3
WO2007046083A3 PCT/IL2006/001168 IL2006001168W WO2007046083A3 WO 2007046083 A3 WO2007046083 A3 WO 2007046083A3 IL 2006001168 W IL2006001168 W IL 2006001168W WO 2007046083 A3 WO2007046083 A3 WO 2007046083A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
eye diseases
treatment
present
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2006/001168
Other languages
French (fr)
Other versions
WO2007046083A2 (en
Inventor
Yoav Sharoni
Joseph Levy
Yoram Sela
Zohar Nir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lycored Ltd
Original Assignee
Lycored Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycored Ltd filed Critical Lycored Ltd
Priority to MX2008004981A priority Critical patent/MX2008004981A/en
Priority to AU2006305546A priority patent/AU2006305546A1/en
Priority to EP06796159A priority patent/EP1937240A2/en
Priority to JP2008535182A priority patent/JP2009515821A/en
Publication of WO2007046083A2 publication Critical patent/WO2007046083A2/en
Priority to IL190779A priority patent/IL190779A0/en
Anticipated expiration legal-status Critical
Publication of WO2007046083A3 publication Critical patent/WO2007046083A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising a mixture of carotenoids and adjuvants, which provides synergistic therapeutic potential. The compositions of the present invention, which can be administered orally or topically to the eye, are useful in preventing, attenuating or treating eye diseases such as age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and cataracts.
PCT/IL2006/001168 2005-10-16 2006-10-05 Compositions for treatment of eye diseases Ceased WO2007046083A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2008004981A MX2008004981A (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases.
AU2006305546A AU2006305546A1 (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases
EP06796159A EP1937240A2 (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases
JP2008535182A JP2009515821A (en) 2005-10-16 2006-10-05 Composition for treating eye diseases
IL190779A IL190779A0 (en) 2005-10-16 2008-04-10 Compositions for treatment of eye diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL171452 2005-10-16
IL17145205 2005-10-16

Publications (2)

Publication Number Publication Date
WO2007046083A2 WO2007046083A2 (en) 2007-04-26
WO2007046083A3 true WO2007046083A3 (en) 2011-05-19

Family

ID=37962894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/001168 Ceased WO2007046083A2 (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases

Country Status (7)

Country Link
EP (1) EP1937240A2 (en)
JP (1) JP2009515821A (en)
AU (1) AU2006305546A1 (en)
IL (1) IL190779A0 (en)
MX (1) MX2008004981A (en)
RU (1) RU2008119234A (en)
WO (1) WO2007046083A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411431B2 (en) 2004-11-09 2014-02-12 カプロン インコーポレイテッド Methods and materials for skin care
JP2010505958A (en) * 2006-10-10 2010-02-25 バーンハム インスティトゥート フォー メディカル リサーチ Neuroprotective compositions and methods
DE202007012373U1 (en) * 2007-09-04 2009-01-08 Omnivision Gmbh Dietary supplements, sachets containing a dietary supplement and use of a dietary supplement
WO2010060729A1 (en) * 2008-11-03 2010-06-03 Giuliani S.P.A. Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
EP3085365A3 (en) * 2009-01-19 2017-01-04 Lycored Ltd. Synergistic combinations of carotenoids and polyphenols
WO2011076869A1 (en) * 2009-12-22 2011-06-30 Aakerlund Hans-Erik Isolated green plant material
JP2011256118A (en) * 2010-06-07 2011-12-22 Kao Corp Il-8 and gm-csf expression inhibitor
EP2624806B1 (en) * 2010-10-04 2017-06-21 Cupron Inc. Cosmetic skin care compositions comprising insoluble copper oxide
AU2012283166B2 (en) * 2011-07-13 2017-05-11 University Of Georgia Research Foundation, Inc. Use of xanthophyll carotenoids to improve visual performance and neural efficiency
CN103798808A (en) * 2012-11-15 2014-05-21 中国科学院大连化学物理研究所 Nutrient formula and application thereof to food or medicine for reliving asthenopia
BR112017002580A2 (en) 2014-08-11 2018-03-27 Univ Louisiana State administration of nanoencapsulated bioactive antioxidants
EP3220934B1 (en) * 2014-11-25 2019-06-12 Lycored Ltd. Biologically-active tomato composition having reduced amount of lycopene
JP6148780B1 (en) * 2016-02-05 2017-06-14 参天製薬株式会社 A composition containing xanthophyll and a processed plant of the genus Hishi
JP7105532B2 (en) * 2017-05-10 2022-07-25 ロート製薬株式会社 Composition for prevention, improvement or treatment of posterior segment disease
WO2019021299A1 (en) * 2017-07-25 2019-01-31 Tathagata Dutta A topical ocular suspension of antioxidants
WO2019087189A1 (en) * 2017-11-01 2019-05-09 Lycored Ltd. A method for improving ocular blood flow
US11696593B2 (en) 2018-08-24 2023-07-11 Bioscience Formulators, LLC Astaxanthin nutritional compositions and uses
JP7005043B2 (en) * 2020-07-08 2022-02-10 株式会社東洋新薬 Retinal protection composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye

Also Published As

Publication number Publication date
WO2007046083A2 (en) 2007-04-26
MX2008004981A (en) 2008-10-17
AU2006305546A1 (en) 2007-04-26
RU2008119234A (en) 2009-11-27
IL190779A0 (en) 2009-02-11
JP2009515821A (en) 2009-04-16
EP1937240A2 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
WO2007046083A3 (en) Compositions for treatment of eye diseases
EP2514423A3 (en) Method of treatment of age-related macular degeneration (AMD)
BRPI0606172A2 (en) methods and compositions for treating eye disorders
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
MX354184B (en) Alkoxy compounds for disease treatment.
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
EA200700109A1 (en) METHODS OF TREATMENT OF OPHTHALMOLOGICAL CONDITIONS (OPTIONS)
BR112014008789A2 (en) prevention and treatment of eye conditions
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2009055006A8 (en) Deuterated darunavir
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
WO2006039327A3 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
EA201100462A1 (en) SERIOUS CONNECTIONS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
WO2008013986A3 (en) Compositions and methods for treating or preventing ophthalmic light toxicity
MX2019008963A (en) Composition containing ursodeoxycholic acid for prevention or treatment of visual impairment.
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
WO2007096886A3 (en) Composition and methods for treating and preventing age-related macular degeneration
WO2004016214A3 (en) Methods and compositions for treatment of macular and retinal disease
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
WO2008008701A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2007089673A8 (en) Compositions and methods for treatment of ophthalmic diseases and disorders
WO2009046405A3 (en) Antibodies to htra1 and methods of using the same
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 190779

Country of ref document: IL

Ref document number: 2006305546

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006796159

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008535182

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004981

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006305546

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008119234

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006796159

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0617420

Country of ref document: BR

Free format text: PEDIDO RETIRADO, UMA VEZ QUE, SEGUNDO O ART. 216 INCISO 2O DA LPI, O DOCUMENTO DE PROCURACAO NAO FOI PROTOCOLADO EM SESSENTA DIAS CONTADOS DA PRATICA DO PRIMEIRO ATO DA PARTE NO PROCESSO, E NAO HOUVE MANIFESTACAO DO REQUERENTE FRENTE A PUBLICACAO DO ARQUIVAMENTO DA PETICAO (11.6.1) NA RPI 2150 DE 20/03/2012.